NCL  
Nanotechnology Characterization Laboratory Skip Navigation
 

Facilities

In addition to collaborative resources located at NIST, the NCL will also have direct access to all resources at the Frederick National Laboratory for Cancer Research (FNL), including those co-located with the NCL at the Advanced Technology Research Facility. The laboratories in of the NCL are outfitted with a tissue culture room, an isotope laboratory, research bays, a cold room, a chromatography and electrophoresis area, microscopy rooms, a spectroscopy area, a synthetic lab with chemical fume hoods, and open floor space for freestanding instrumentation and equipment.

Relationship to Leidos Biomedical Research

The NCL is a government-owned, contractor-operated (GOCO) facility under NCI's federally funded research and development center (FFRDC) and will fall under NCI-Frederick's Operations and Technical Support (OTS) contract. Leidos Biomedical Research, Inc., a subsidiary of Leidos, is the OTS contractor for the Frederick National Laboratory for Cancer Research. The mission of Leidos Biomedical Research, Inc., is to provide scientific, technical, management, administrative, and logistical support to NIH intramural laboratory research and development related to the causes of and cures for cancer and AIDS.

Leidos Biomedical Research, Inc., is one of four related NCI contracts on site and serves as the infrastructure support for the entire center. The contract is the largest single research contract awarded by the U.S. Department of Health and Human Services (DHHS) and it is the Department's only government-owned, contractor-operated facility contract. Leidos Biomedical Research, Inc. employs over 1,500 staff including scientists, research assistants, technicians, engineers, administrative, maintenance, and support personnel.

Leidos Biomedical Research operates under a variety of regulatory, performance, and quality standards.
These include:

  • Leidos Biomedical Research operates the NCI's Biopharmaceutical Development Program and the NIAID/Vaccine Research Center's Vaccine Pilot Plant. Both programs manufacture pharmaceuticals for use in human clinical trials. These products are manufactured in accordance with FDA requirements for Current Good Manufacturing Practices 21CFR Chapter 1 Parts 210 and 211 and Biological Products Requirements 21 CFR Chapter 1 Parts 600 and 610.
  • Leidos Biomedical Research clinical testing laboratories in accordance with 42 CRF Part 493 "Clinical Laboratory Improvement Amendments (CLIA)."
  • Leidos Biomedical Research research laboratories are operated in accordance with 21 CFR Part 58 "Good Laboratory Practice for Nonclinical Laboratory Studies."
  • NCI-Frederick laboratory animal science programs, operated by Leidos Biomedical Research, are AAALAC accredited (Association for Accreditation and Assessment Laboratory Animal Care) and operated in accordance with the Guide for the Care and Use of Laboratory Animals and Public Health Service Policies. NCI-Frederick maintains an Assurance through the NIH Office of Animal Care and Use.
 
       
       
National Cancer InstituteDepartment of Health and Human ServicesNational Institutes of HealthFirstGov.govNCI - Alliance for Nanotechnology in Cancer
National Cancer Institute U.S. National Institutes of Health www.cancer.gov Nanotechnology Characterization Lab